喜讯！威凯尔医药入选2021年度南京市培育独角兽企业
Published Time:
2021-10-14 11:07
Source:
6月23日， 2021年南京市独角兽、瞪羚企业发布会在上秦淮国际文化交流中心隆重召开。大会上，市领导发布《2021年南京市独角兽、瞪羚企业发展白皮书》，并为独角兽企业、培育独角兽和瞪羚企业代表授牌。江苏威凯尔医药科技有限公司(以下简称“威凯尔医药”)荣誉入选为2021年南京市培育独角兽企业。
此次入选“2021年南京市培育独角兽企业”榜单是南京市政府以及江北新区政府对威凯尔医药研发实力和创新能力的肯定。未来，威凯尔医药将继续以创新驱动发展，不断提升科技创新水平和行业影响力，加快创新成果转化，为南京江北新区生物医药发展注入新活力。
2021年南京市培育独角兽企业名单
|
序号 |
企业简称 |
企业名称 |
行业 |
融资轮次 |
板块 |
|
1 |
维立志博 |
南京维立志博生物科技有限公司 |
生物医药 |
B轮 |
江北新区 |
|
2 |
和鼎 |
和鼎（南京）医药技术有限公司 |
生物医药 |
B轮 |
江北新区 |
|
3 |
博奥信 |
博奥信生物技术（南京）有限公司 |
生物医药 |
Pre-轮 |
江北新区 |
|
4 |
徐诺药业 |
徐诺药业（南京）有限公司 |
生物医药 |
C轮 |
江北新区 |
|
5 |
威凯尔 |
江苏威凯尔医药科技有限公司 |
生物医药 |
A轮 |
江北新区 |
|
6 |
南京诺尔曼生物 |
南京诺尔曼生物技术股份有限公司 |
生物医药 |
D轮 |
江北新区 |
|
7 |
集萃药康 |
江苏集萃药康生物科技股份有限公司 |
生物医药 |
B轮 |
江北新区 |
|
8 |
中科超精 |
中科超精（南京）科技有限公司 |
生物医药 |
A轮 |
江北新区 |
|
9 |
轩凯生物 |
南京轩凯生物科技股份有限公司 |
生物医药 |
B轮 |
江北新区 |
|
10 |
擎天全税通 |
南京擎天全税通信息科技有限公司 |
IT |
A轮 |
江北新区 |
独角兽企业：是指自成立起十年内获得过私募投资，尚未上市(不含新三板)，且最新一轮市场融资估值超过10亿美元的企业。
培育独角兽企业：是指自成立起十年内获得过私募投资，尚未上市(不含新三板)，且最新一轮市场融资估值超过1亿美元的企业(制造业企业估值≥5000万美元)。
瞪羚企业：是指成功跨越创业死亡谷，商业模式得到市场认可，进入高速成长阶段的创新型企业，具有成长速度快、创新能力强、专业领域新、发展潜力大等特征。起始年收入不低于500万元人民币(制造业企业不低于300万元人民币)，且连续3年增长率不低于50%(制造企业不低于20%)。
Previous Page
Next Page
Previous Page
Next Page
Related News
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
View Details
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
View Details
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
View Details
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn